Drug
Eribulin clinical trials
Also written Halaven, E7389 and ER-086526.
Includes 2 studies of Liposomal Eribulin Mesylate.
- studies test it
- 134
- open now
- 7
- in phase 3
- 12
- first study started
- 2002
Keep track of what changes. Save the eribulin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
134 studies that test it; most in 2014 (13)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2003 | 2 |
| 2004 | 2 |
| 2005 | 1 |
| 2006 | 12 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 5 |
| 2010 | 6 |
| 2011 | 11 |
| 2012 | 10 |
| 2013 | 7 |
| 2014 | 13 |
| 2015 | 9 |
| 2016 | 4 |
| 2017 | 5 |
| 2018 | 12 |
| 2019 | 5 |
| 2020 | 3 |
| 2021 | 7 |
| 2022 | 4 |
| 2023 | 3 |
| 2024 | 4 |
| 2025 | 4 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 47
- Phase 2
- 84
- Phase 3
- 12
- Phase 4
- 4
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 49 · Other 85
Eisai Inc. (29) · National Cancer Institute (NCI) (14) · Eisai Co., Ltd. (7) · Dana-Farber Cancer Institute (5) · MedSIR (5) · Eisai Limited (5) · M.D. Anderson Cancer Center (4) · Fudan University (3)
Often tested with
Tested in the same studies.
Gemcitabine (7) · Capecitabine (7) · Carboplatin (6) · Paclitaxel (5) · Vinorelbine (4) · Trastuzumab (4) · Cyclophosphamide (4) · Irinotecan (4)
Studies
Open first, then newest update. How each study uses eribulin is read from its arms, and is right about nine times in ten.
Testing it · 134
- Scalp Cooling in MBCRecruitingPhase 2Dana-Farber Cancer InstituteNCT04986579Written as Eribulin
- Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and LeiomyosarcomaRecruitingPhase 1Washington University School of MedicineNCT06957431Written as Eribulin
- A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid TumorsRecruitingPhase 1M.D. Anderson Cancer CenterNCT06006273Written as Eribulin
- Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast CancerRecruitingPhase 3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06889688Written as Camrelizumab+Apatinib+Eribulin
- Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negative Breast Cancer)Not yet recruitingPhase 2Sun Yat-sen UniversityNCT07255612Written as Eribulin
- A Multicenter, Single-arm, Prospective Phase II Clinical Study of Epalrotokewali Combined With Eribulin, Anlotinib, and Radiotherapy for the Treatment of Patients With Advanced Soft Tissue Sarcoma.Not yet recruitingPhase 2Fudan UniversityNCT07205185Written as QL1706 + Eribulin + Anlotinib + Radiotherapy
- Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical TrialNot yet recruitingPhase 2Zhejiang Cancer HospitalNCT06308939Written as Eribulin
- Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial CancerActive, not recruitingPhase 3National Cancer Institute (NCI)NCT04579224Written as Eribulin Mesylate
- Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor FailureTerminatedPhase 1/2Henan Cancer HospitalNCT05335473Written as Eribulin and Tucidinostat
- A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid TumorActive, not recruitingPhase 1/2Eisai Co., Ltd.NCT04078295Written as E7389-LF
- Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain TumorsCompletedEarly Phase 1City of Hope Medical CenterNCT02338037Written as Eribulin Mesylate
- Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney DysfunctionActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT00365157Written as Eribulin Mesylate
- Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)CompletedPhase 2Massachusetts General HospitalNCT03331250Written as Eribulin
- Study of E7389 Liposomal Formulation in Participants With Solid TumorActive, not recruitingPhase 1Eisai Co., Ltd.NCT03207672Written as E7389-LF
- Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial CancerActive, not recruitingPhase 2National Cancer Institute (NCI)NCT03237780Written as Eribulin Mesylate
- A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)Active, not recruitingPhase 3Sichuan Baili Pharmaceutical Co., Ltd.NCT06343948Written as Eribulin
- A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)Active, not recruitingPhase 3Sichuan Baili Pharmaceutical Co., Ltd.NCT06382142Written as Eribulin
- Tucatinib+Trastuzumab+Eribulin in HER2+ MBCActive, not recruitingPhase 2Criterium, Inc.NCT05458674Written as Eribulin
- A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast CancerActive, not recruitingPhase 2Dana-Farber Cancer InstituteNCT02623972Written as Eribulin
- Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by SurgeryActive, not recruitingPhase 1OHSU Knight Cancer InstituteNCT03361436Written as Eribulin Mesylate
See all 134 studies that test eribulin →
Given in every arm · 33 — eribulin is usual care beside what is tested
- ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast CancerRecruitingPhase 3BioNTech SENCT07173751Written as Eribulin
- ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast CancerRecruitingPhase 2ALX Oncology Inc.NCT07007559Written as Eribulin
- A Phase II Study of HLX22 in Combination With Trastuzumab and Chemotherapy in HER2-Positive Locally Advanced or Metastatic Breast Cancer PatientsNot yet recruitingPhase 2Shanghai Henlius BiotechNCT07824869Written as Eribulin
- A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast CancersNot yet recruitingPhase 1/2Advenchen Pharmaceuticals, LLC.NCT07811232Written as Eribulin
- A Study of SDX-7320 in Combination With Eribulin for People With Breast CancerRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT05570253Written as Eribulin
- Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast CancerNot yet recruitingPhase 1/2MedSIRNCT07494448Written as Eribulin Mesilate injection
- A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast CancerRecruitingPhase 3Jazz PharmaceuticalsNCT06435429Written as Eribulin
- Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast CancerRecruitingPhase 1/2Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT06942234Written as Eribulin
- JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBCNot yet recruitingPhase 2Fudan UniversityNCT06731153Written as Eribulin
- A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)RecruitingPhase 1/2GI Innovation, Inc.NCT05824975Written as eribulin
- Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast CancerNot yet recruitingPhase 2Wang JiayuNCT06539559Written as Eribulin
- LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast CancerRecruitingPhase 2Fudan UniversityNCT06387628Written as Eribulin
- Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast CancerRecruitingPhase 2Fudan UniversityNCT06355037Written as Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum
- A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast CancerRecruitingPhase 1/2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06202261Written as Eribulin mesylate injection
- Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast CancerNot yet recruitingPhase 2Shengjing HospitalNCT06202313Written as Eribulin
- EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine CarcinosarcomaCompletedPhase 2Australia New Zealand Gynaecological Oncology GroupNCT05619913Written as Eribulin Mesylate
- Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast CancerActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT04345913Written as Eribulin Mesylate
- Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With ChemotherapyActive, not recruitingPhase 2BioNTech SENCT06449222Written as Eribulin
- Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast CancerActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT03202316Written as Eribulin
- ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast CancerActive, not recruitingPhase 1Enliven TherapeuticsNCT06328738Written as Eribulin
Showing 20 of 33.
As the comparator · 23 — what is tested is compared with eribulin
- A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)RecruitingPhase 3Intensity Therapeutics, Inc.NCT06263231Written as Eribulin
- YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast CancerRecruitingPhase 3MediLink Therapeutics (Suzhou) Co., Ltd.NCT07461454Written as Eribulin
- Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast CancerRecruitingPhase 3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.NCT06081959Written as Eribulin
- Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast CancerRecruitingPhase 2Seoul National University HospitalNCT05530057Written as Eribulin Mesylate
- JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer SubjectsRecruitingPhase 3Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT06079983Written as Eribulin mesylate injection
- Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast CancerRecruitingPhase 3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06255392Written as Eribulin mesylate injection
- Organoid-based Functional Precision Therapy for Advanced Breast CancerRecruitingPhase 2Guangdong Provincial People's HospitalNCT06102824Written as Eribulin
- Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast CancerRecruitingPhase 3Sun Yat-sen UniversityNCT06268652Written as Eribulin
- A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast CancerActive, not recruitingPhase 3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.NCT06279364Written as Eribulin
- Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in PIK3CA-mutated HER2+ Advanced BC (ALPHABET)TerminatedPhase 3Spanish Breast Cancer Research GroupNCT05063786Written as Eribulin
- Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]CompletedPhase 3Daiichi SankyoNCT03734029Written as Eribulin
- A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)Active, not recruitingPhase 3AstraZenecaNCT05104866Written as Eribulin
- SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical TrialActive, not recruitingPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT05814354Written as Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel
- A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)Active, not recruitingPhase 3AstraZenecaNCT05374512Written as Eribulin mesylate
- Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)Active, not recruitingPhase 3Gilead SciencesNCT04639986Written as Eribulin Mesylate Injection
- FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast CancerActive, not recruitingPhase 3Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.NCT06519370Written as Eribulin
- SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast CancerActive, not recruitingPhase 2UNICANCERNCT02299999Written as Eribulin
- Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast CancerStatus unknownPhase 3Shanghai Yizhong Pharmaceutical Co., Ltd.NCT06143553Written as Eribulin Mesilate injection
- Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast CancerCompletedPhase 3Gilead SciencesNCT03901339Written as Eribulin
- A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and CapecitabineCompletedPhase 3Nektar TherapeuticsNCT02915744Written as Eribulin
Showing 20 of 23.
Codes
What other systems call eribulin · ClinicalTrials.gg INT004696
- MeSH (NLM) C490954eribulinConfirmed NLM, Wikidata
- UNII (FDA) LR24G6354GERIBULINConfirmed FDA, NLM, Wikidata
- RxNorm 1045453Confirmed FDA, Wikidata
- Wikidata Q408717eribulinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C96748EribulinOne source FDA
- DrugBank DB08871One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C490954 | eribulin | Confirmed NLM, Wikidata |
| UNII (FDA) | LR24G6354G | ERIBULIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1045453 | — | Confirmed FDA, Wikidata |
| Wikidata | Q408717 | eribulin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C96748 | Eribulin | One source FDA |
| DrugBank | DB08871 | — | One source Wikidata |
Also registered as eribulin mesylate (UNII AV9U0660CW · RxNorm 1045452).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.